Idiopathic Parkinson's Tremors: Treatment Options The study examines the clinical importance of tremors in idiopathic Parkinson's disease (iPD) and the difficulties encountered in their management. It underscores the diversity of iPD patients and the various symptoms they experience, notably tremors, which significantly affect their quality of life. Despite historical efforts to
Tag: neurology
Ganaxolone Treatment For Refractory Epilepsy
Ganaxolone Treatment For Refractory Epilepsy Overview In a meta-analysis conducted to evaluate the use of ganaxolone for refractory epilepsy, researchers collected data from four randomized controlled trials involving a total of 659 patients. The analysis revealed that ganaxolone significantly improved the reduction in mean seizure frequency by ≥50% when compared to a
Diabetic Peripheral Neuropathy Diagnosis Using Nerve Ultrasonography
Diabetic Peripheral Neuropathy Diagnosis Using Nerve Ultrasonography Overview The conventional diagnostic modality for diabetic peripheral neuropathy is via the use of nerve conduction studies (NCS), however, this investigation does not evaluate or demonstrate the structure of the nerve. This research was aimed at investigating the use of peripheral nerve ultrasonography as a
nusinersen therapy for pediatric spinal muscular atrophy
nusinersen therapy for pediatric spinal muscular atrophy Study Background Spinal muscular atrophy (SMA) is an inherited motor neuron disease caused by the degeneration of anterior horn cells of the spinal cord and brainstem. SMA primarily affects babies and young children and has an incidence of 1:10,000. It is caused by a homozygous
Stroke in the Presence of Renal Disease
Can Sotagliflozin Prevent Cardiovascular Ailments for Patients with Diabetes and Chronic Kidney Disease?
Can Sotagliflozin Prevent Cardiovascular Ailments for Patients with Diabetes and Chronic Kidney Disease Cardiovascular diseases, including stroke, are major healthcare issues affecting humans worldwide. Between 2010 and 2030, the estimated total medical costs might escalate to from $273–$818 billion in the United States alone. Modifiable risk factors for stroke include hypertension, diabetes,
